This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Medical Ethics  • Psoriasis  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

We wish to respond to Dr Katz’s comments regarding advertisements for AMEVIVE (alefacept). Biogen Idec, Inc, holds its advertising to a high standard based on ethics and compliance with applicable law and regulations. The Food, Drug, and Cosmetic Act and federal regulations require advertising for a prescription drug or biologic product to be consistent with the information included in the product labeling. The approval of AMEVIVE was based on data from 2 phase 3 randomized, double-blind, placebo-controlled clinical studies. These registrational studies evaluated patients treated with either the IV or the IM formulation. Both studies provided key data in support of the product approval and are described in the product labeling.

The advertisement referred to by Dr Katz is consistent with the product labeling for AMEVIVE. The particular conclusions made by Dr Katz are inaccurate, and our responses to each of his inaccurate conclusions follow. First, the data . . . [Full Text of this Article]

AUTHOR INFORMATION
Barry Ticho, MD, PhD; Thorsten Eickenhorst, MD

RELATED ARTICLE

AMEVIVE’s Advertisements: Problematic?
Kenneth A. Katz
Arch Dermatol. 2005;141(12):1602-1604.
EXTRACT | FULL TEXT